Nachrichten zur Pfizer Aktie

Prediction: Pfizer Wont Acquire Viking Therapeutics. Heres Why.

…

[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Hemophilia B Drug Market Size and Share to Grow by 2032, Assesses DelveInsight | Key Emerging Therapies - CSL222, SerpinPC, AskBio009, PF-06838435/fida, Marstacimab, FLT180a, Concizumab, Fitusiran

The current therapeutic landscape of hemophilia B in the 7MM is driven by several approved therapies. The hemophilia B market…

Astra, Pfizer Boost China Bets Despite US Drive to Decouple

The chief executive officers of AstraZeneca Plc and Pfizer Inc. pledged to support expansion of China’s biopharmaceutical industry, even as…

Pfizer: Diesen Rückzugsbereich müssen Anleger kennen! Chartanalyse

Düsseldorf (www.aktiencheck.de) - Pfizer-Chartanalyse von HSBC Trinkaus & Burkhardt: Die Analysten von HSBC Trinkaus & Burkhardt nehmen in einer aktuellen Aktienanalyse…

Will Pfizer Be a Trillion-Dollar Stock by 2035?

A market cap of $1 trillion for Pfizer over the next 11 or so years? Possible, but not probable.…

Will Pfizer Be a Trillion-Dollar Stock by 2035? @themotleyfool #stocks $PFE

A market cap of $1 trillion for Pfizer over the next 11 or so years? Possible, but not probable.…

Will Pfizer Be a Trillion-Dollar Stock by 2035?

…

Argus downgrades Pfizer, lowers earnings estimates on near-term headwinds By Investing.com

Argus downgrades Pfizer, lowers earnings estimates on near-term headwinds…

Pfizer: Kurzfristiger Gegenwind - Die Aktie abgestuft - Aktienanalyse

New York (www.aktiencheck.de) - Pfizer-Aktienanalyse von Argus Research: Die Analysten von Argus Research stufen die Aktie von Pfizer Inc. (ISIN: US7170811035,…

Pfizer: Guggenheim überarbeitet Modelle für Large-Cap-Biopharmazieunternehmen - Aktienanalyse

New York (www.aktiencheck.de) - Pfizer-Aktienanalyse von Guggenheim Securities: Die Analysten von Guggenheim Securities senken in einer aktuellen Aktienanalyse ihr Kursziel für…

Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates

AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower…

Community Oncology Services Global Market Report 2024

Dublin, March 21, 2024 (GLOBE NEWSWIRE) -- The "Community Oncology Services Global Market Report 2024" report has been…

Is Pfizer the Best Dividend Stock for You?

…

Is Pfizer the Best Dividend Stock for You?

Pfizers stock is cheap, and it pays an incredibly high yield right now.…

Is Pfizer the Best Dividend Stock for You? @themotleyfool #stocks $PFE

Pfizers stock is cheap, and it pays an incredibly high yield right now.…

Gewinneinbruch bei Biontech nach Pandemieende - Erstes Krebsmittel 2026 erwartet

Frankfurt (Reuters) - Das Mainzer Biotechunternehmen Biontech hat im vergangenen Jahr den Nachfrageeinbruch bei Corona-Impfstoffen zu spüren bekommen.

Der Umsatz…

Pfizer sells £3B of shares in Haleon

…

Pfizer offloads $3.9 billion stake in Sensodyne-maker Haleon

…

Pfizer offloads $3.9 billion stake in Sensodyne-maker Haleon By Reuters

Pfizer offloads $3.9 billion stake in Sensodyne-maker Haleon…

Pfizer upsizes Haleon stake sale

Haleon PLC (LSE:HLN, NYSE:HLN) said Pfizer Inc (NYSE:PFE, ETR:PFE) had sold a larger than expected amount of its shares overnight, scooping…

Pfizer Sells £3 Billion of Shares in Sensodyne Maker Haleon

Pfizer Inc. has sold over £3 billion ($3.8 billion) of shares in Haleon Plc, the first step by the UK…

Pfizer (PFE) to Decrease Stake in Haleon From 32% to 24%

Pfizer (PFE) plans to sell some shares of consumer healthcare firm Haleon (HLN), which it owns, to bring down its…

Pfizer Is Selling a Chunk of Its Haleon Stock. It’s a $3 Billion Windfall.

…

5 Reasons Why Buying This 6%-Yielding Dividend Stock Could Be a Brilliant Move @themotleyfool #stocks $PFE

Pfizer just might be one of the biggest comeback stories of the second half of this decade.…

Pfizer to trim its Haleon stake to 24% By Investing.com

Pfizer to trim its Haleon stake to 24%…

Pfizer reduziert Haleon-Anteil auf 24 Prozent

Von Elena Vardon BARCELONA (Dow Jones)--Pfizer will rund 630 Millionen seiner Haleon-Aktien auf den Markt werfen und dadurch seine…

Pfizer to sell down stake in Haleon

Pfizer Inc (NYSE:PFE, ETR:PFE) has confirmed it will sell a large chunk of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), raising…

Pfizer to sell down stake in Haleon

Pfizer Inc (NYSE:PFE, ETR:PFE) has confirmed it will sell a large chunk of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), raising…

Pfizer to cut stake in Sensodyne toothpaste-maker Haleon to 24%

…

Consumer healthcare giant Haleon says Pfizer to cut stake to 24% By Reuters

Consumer healthcare giant Haleon says Pfizer to cut stake to 24%…

Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns

…

Is Pfizer Stock a Millionaire Maker?

A couple of years ago, Pfizers shares may have seemed like a sure thing. That may not be the case…

Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market? @themotleyfool #stocks $PFE $LLY $NVO $VKTX $ALT

Viking Therapeutics just might be an attractive acquisition target for Pfizer.…

Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?

Viking Therapeutics just might be an attractive acquisition target for Pfizer.…

Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?

…

How To Earn $500 A Month From Pfizer Stock After A Surprise Profit-Turning Quarter

…

Deutsche Biotech-Hoffnung Tubulis holt Top-Investoren an Bord – Börsengang ist "immer eine Option"

Der Markt für Antikörper-Wirkstoff-Konjugate, den sogenannten ADCs, bleibt siedend heiß. In den USA gab es in den vergangenen Quartalen in…

Deutsche Biotech-Hoffnung Tubulis holt Top-Investoren an Bord – Börsengang ist "immer eine Option"

Der Markt für Antikörper-Wirkstoff-Konjugate, den sogenannten ADCs, bleibt siedend heiß. In den USA gab es in den vergangenen Quartalen in…

Pfizer Aktie: Anhaltende Erholung oder Täuschung?

Die Pfizer-Aktie wird derzeit zu einem Preis von 25,7 € gehandelt, was einer leichten 7-Tages-Verringerung von 0,96% entspricht. Eine jüngste…

Pfizers (PFE) Adcetris Meets Survival Goal in Lymphoma Study

Pfizer (PFE) plans to seek approval for the eighth indication for Adcetris based on data from the ECHELON-3 study.…

Pfizer Inc. (PFE) Leerink Partners Global Biopharma Conference 2024 - (Transcript)

…

Pfizer: Seagen Acquisition Starting To Bear Fruit

…

Pfizer: Its Darkest Before The Dawn, Upgrading To Strong Buy

…

Neuroendocrine Tumor Treatment Market revenue to hit USD 8 Billion by 2035, says Research Nester

Leading neuroendocrine tumor treatment market players include BoehringerIngelheim International GmbH, Hutchison MediPharma Limited, AVEO Oncology, Pfizer, Inc., IpsenPharma, Tarveda Therapeutics,…

Pfizer-Aktie heute gut behauptet: Aktienwert steigt (25,9583 €)

Am US-amerikanischen Aktienmarkt notiert das Wertpapier von Pfizer gegenwärtig ein wenig fester. Die Aktie kostete zuletzt 28,36 US-Dollar. Die Pfizer-Aktie…

Sensationelle Studienergebnisse - Hautkrebs vollständig geheilt. 797% Biotech Hot Stock nach 10.996% mit Pfizer ($PFE)

London (www.aktiencheck.de, Anzeige) EinschätzungStrong OutperformerKurszieleKursziel 12M: 2,50 EUR Kurschance: 541% Kursziel 24M: 3,50 EUR Kurschance: 797%StammdatenISIN: GB00BM9XQ619 WKN: A3DTUQ Ticker: T9G.HMKursdatenKurs: 0,390 EUR 52W Hoch: 1,630 EUR 52W…

dpa-AFX ProFeed